Skip to main content

Table 1 Summary of studies and treatment arms included in the primary mixed treatment comparison analysis

From: Once-daily fluticasone furoate/vilanterol versus twice daily combination therapies in asthma–mixed treatment comparisons of clinical efficacy

  N (%)   N (%)
Total studies 31 Total treatment arms 75
Endpoint reported   Placebo 2 (3)
Change from baseline in FEV1 28 (90) FF/VI 92/22 QD 3 (4)
Change from baseline in PEF 18 (58) FF/VI 184/22 QD 1 (1)
Annual rate of exacerbations 6 (19) FF 100 QD 2 (3)
Change from baseline in AQLQ 7 (23) FF 200 QD 1 (1)
Mean age reported 41.74 FP/SAL 100/50 BID 8 (11)
Mean percent male 40.51 FP/SAL 250/50 BID 11 (15)
Mean baseline FEV1 2.30 FP/SAL 500/50 BID 5 (7)
   BUD/FORM 320/9 BID 12 (16)
   BUD/FORM 640/18 BID 1 (1)
   BUD/FORM 80/4.5 BID 2 (3)
   BUD 360 BID 5 (7)
   BUD 640 BID 2 (3)
   BUD 360 BID 1 (1)
   BUD 80 BID 1 (1)
   BDP (HFA extra-fine)/FORM 200/12 BID 2 (3)
   FORM 9 BID 1 (1)
   FP 250 BID 3 (4)
   FP 500 BID 4 (5)
   FP 100 BID 1 (1)
   FP 100 BID + Montelukast 10 QD 3 (4)
   FP/FORM 250/10 BID 1 (1)
   MMF/F 200/10 BID 2 (3)
   MMF/F 400/10 BID 1 (1)
  1. Note: All stated doses are mcg. Delivered doses are given for FF/VI at the strengths licenced in Europe for the treatment of asthma, and for BUD/FORM. For all other treatments, nominal doses are given
  2. AQLQ Asthma quality of life questionnaire, BDP Beclomethasone dipropionate, BID Twice daily, BUD Budesonide, FORM Formoterol, FEV 1 Forced expiratory volume in one s, FF Fluticasone furoate, FP Fluticasone propionate, HFA Hydrofluoroalkane, MMF Mometasone furoate, PEF Peak expiratory flow, QD once daily, SAL Salmeterol, TIO Tiotropium, VI Vilanterol